Merrimack Pharmaceuticals stock plunges on disappointing trial of cancer drug

Merrimack’s drug testing targeted a type of  ovarian cancer.
Merrimack’s drug testing targeted a type of ovarian

This is a summary. To read the whole story subscribe to

Merrimack Pharmaceuticals Inc., a Cambridge company focused on developing cancer therapies, fell after it reported results from a mid-stage study involving the drug MM-121 in combination with Paclitaxel to treat platinum-resistant or refractory-advanced ovarian cancer. MM-121, being developed with Sanofi, did not meet its primary “endpoint” of improving progression-free survival. There was no statistical difference between MM-121 with Paclitaxel and Paclitaxel alone. Side effects like diarrhea and vomiting were more prevalent in the group taking MM-121.

Full story for subscribers.

Get the full story with unlimited access to

Just 99 cents for four weeks.